BENGALURU / NEW DELHI — India’s drug quality standards have come under increased scrutiny at home and overseas in recent years after locally made cough syrups were linked to the deaths of children in India and also in countries including Gambia and Uzbekistan. The development, reported on October 30, 2026, has drawn close scrutiny from domain specialists and policy observers examining its wider operational and institutional impact.
Industry executives and digital policy researchers noted that the rapid evolution of enterprise compute infrastructure, artificial intelligence deployment, and cybersecurity compliance standards is reshaping operational priorities across India’s technology corridor.
Regulatory frameworks governing data protection, platform accountability, and sovereign cloud capacity continue to draw sustained engagement from both global technology firms and domestic startups.
- De-notification of MSMER-2023 eliminates overlapping procedures, but will it safeguard the standards of medical education?
- Financial protection for patients cannot be achieved through a single intervention: former National Health Authority CEO
- Why ongoing symptoms and patients’ lived experiences need more attention in lupus care
